[Skip to Content]
[Skip to Content Landing]
Article
November 1983

Long-term Follow-up of Patients Receiving AprindineSafety and Efficacy

Author Affiliations

From the Section of Cardiology, Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois, Chicago. Dr Strasberg is currently with the Coronary Care Unit, Beilinson Medical Center, Petah Tiqva, Israel.

Arch Intern Med. 1983;143(11):2131-2133. doi:10.1001/archinte.1983.00350110117024
Abstract

• Aprindine hydrochloride is an antiarrhythmic agent presently undergoing clinical trials in the United States. Because of the narrow therapeutic-toxic ratio observed for aprindine, the long-term follow-up of these patients is important in determining the potential clinical effectiveness of this drug. In this report we examine our experience with 30 patients with drug-resistant arrhythmias who were discharged receiving aprindine and who were followed up for a mean period of 25 months.

(Arch Intern Med 1983;143:2131-2133)

×